| Grifols Moves Deeper Into Proteome R&D With $146M Deal for Alkahest | Frank Vinluan | 09/08/20 | San Francisco |
| IgGenix Grabs $10M to Advance Antibody Treatments for Allergies | Sarah de Crescenzo | 08/05/20 | San Francisco |
| Amid Boom Days for Biotech, Inhibrx Lines Up Another IPO Effort | Sarah de Crescenzo | 07/29/20 | San Diego |
| Olema Adds $54M to Start Human Tests of Breast Cancer Drug Candidate | Sarah de Crescenzo | 07/22/20 | San Francisco |
| Viela Bio Gets FDA Green Light for Rare Autoimmune Disease Treatment | Sarah de Crescenzo | 06/12/20 | National |
| Accent, AstraZeneca Ink Cancer Drug Deal to Block RNA-Modifying Proteins | Sarah de Crescenzo | 06/04/20 | Boston |
| Insitro Adds $143M to Fuel Machine Learning-Driven Drug Development | Sarah de Crescenzo | 05/26/20 | San Francisco |
| Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments | Sarah de Crescenzo | 05/26/20 | San Diego |
| Aspen Neuro Adds $70M to Test Parkinson’s Cell Therapy in the Clinic | Sarah de Crescenzo | 04/01/20 | San Diego |
| Forge Inks Roche Deal For Antibiotic Aimed at Drug-Resistant Infections | Sarah de Crescenzo | 03/26/20 | San Diego |
| Regenacy Pharma Raises $30M for Nerve Function Restoring Treatments | Sarah de Crescenzo | 03/25/20 | Boston |
| Keros Outlines IPO Plans Amid Markets Rocked by Coronavirus Pandemic | Sarah de Crescenzo | 03/23/20 | Boston |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| Silverback Therapeutics Adds $79M to Test HER2+ Tumor-Targeting Drug | Sarah de Crescenzo | 03/11/20 | Seattle |
| Culture Biosciences Adds $15M for New Software, Bioreactor Expansion | Gareth Macdonald | 03/05/20 | San Francisco |
| Amunix Raises $73M to Bring Safer T Cell Engagers to Solid Tumors | Sarah de Crescenzo | 03/04/20 | San Francisco |
| Quench Bio Springs From Atlas With $50M for a New Take on Inflammation | Frank Vinluan | 01/27/20 | Boston |
| Neurocrine, in Second Epilepsy Deal, Pairs With Swiss Biotech Idorsia | Sarah de Crescenzo | 01/11/20 | San Diego |
| Eying Cancer Combos, Sanofi to Splash Out $2.5B on San Diego’s Synthorx | Sarah de Crescenzo | 12/09/19 | San Diego |
| Astellas Bets On Gene Therapy With $3B Audentes Acquisition Offer | Sarah de Crescenzo | 12/03/19 | National |
| Reata’s Kidney Drug Hits Goals of Key Study, Paves Way for FDA Filing | Sarah de Crescenzo | 11/12/19 | Texas |
| Disc Medicine Launches With $50M to Advance New Anemia Treatments | Sarah de Crescenzo | 10/29/19 | Boston |
| Can Ford’s Self-Driving Car Business Improve Austin’s Traffic Woes? | David Holley | 10/01/19 | Texas |
| Molecular Assemblies Raises $12M to Advance Enzymatic DNA Synthesis | Sarah de Crescenzo | 10/01/19 | San Diego |
| Boston Tech Watch: DataRobot, IBM-MIT, Firefly, Aliro, Embr & More | Brian Dowling | 09/20/19 | Boston |
| Tocagen Stock Tanks After Gene Therapy Drug for Brain Cancer Fails | Sarah de Crescenzo | 09/12/19 | San Diego |
| Glow Snags $2.3M to Help Podcasters Connect to Listeners, Make Money | Jeff Buchanan | 08/08/19 | Seattle |
| TScan Lands $48M for Better, Safer T-Cell Receptor Cancer Therapies | Frank Vinluan | 07/24/19 | Boston |
| VMWare Plans to Acquire Bitfusion for Application-Enhancing Software | David Holley | 07/18/19 | Texas |
| Grocer H-E-B Explores Autonomous Delivery With SF-Area Startup Udelv | David Holley | 07/10/19 | Texas |
